Showing results (111-120 of 120) with videos related to
Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Chemico-Biological Interactions|August 28, 2018
Deoxypodophyllotoxin in Anthriscus sylvestris alleviates fat accumulation in the liver via AMP-activated protein kinase, impeding SREBP-1c signalKwang-Youn Kim, Kwang-Il Park, Seul Gi Lee, et al.Gastroenterology|March 7, 2021
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel DiseaseStefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, et al.Open Forum Infectious Diseases|March 17, 2022
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019Anca Streinu-Cercel, Oana Săndulescu, Liliana-Lucia Preotescu, et al.Journal of Korean Medical Science|December 8, 2017
Lead, Mercury, and Cadmium Exposure in the Korean General PopulationSang Yong Eom, Young Sub Lee, Seul Gi Lee, et al.Chemico-Biological Interactions|December 6, 2016
Liqustri lucidi Fructus inhibits hepatic injury and functions as an antioxidant by activation of AMP-activated protein kinase in vivo and in vitroHye Lim Seo, Su Youn Baek, Eun Hye Lee, et al.Inflammatory Bowel Diseases|April 29, 2025
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC StudiesStefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, et al.Rheumatology (Oxford, England)|November 24, 2020
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trialRene Westhovens, Piotr Wiland, Marek Zawadzki, et al.Clinical Therapeutics|September 23, 2021
Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 InfectionJin Yong Kim, Young Rock Jang, Jang Hee Hong, et al.Open Forum Infectious Diseases|August 31, 2022
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019Jin Yong Kim, Oana Săndulescu, Liliana-Lucia Preotescu, et al.Nature Communications|February 19, 2024
PIBF1 regulates trophoblast syncytialization and promotes cardiovascular developmentJong Geol Lee, Jung-Min Yon, Globinna Kim, et al.Pageof 12